Efficacy, safety and tolerability of using abatacept for the treatment of rheumatoid arthritis

Brazilian Journal of Pharmaceutical Sciences

Volumn 48, Issue 4, 2012, Pages 781-791

  Venson, Rafael ^a   Wiens, Astrid ^a   Correr, Cassyano Januário ^a   Pontarolo, Roberto ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Abatacept efficacy; Meta analyses; Rheumatoid arthritis treatment

Indexed keywords

ABATACEPT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; METHOTREXATE; PLACEBO;

ACR20; ACR50; ACR70; ARTICLE; DAS28; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; INFECTION; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; SCORING SYSTEM; SYSTEMATIC REVIEW;

EID: 84874227705     PISSN: 19848250     EISSN: 21759790     Source Type: Journal    
DOI: 10.1590/S1984-82502012000400022     Document Type: Article

References (31)

1. BAGUST, A.; BOLAND, A.; HOCKENHULL, J.; FLEEMAN, N.; GREENHALGH, J.; DUNDAR, Y.; PROUDLOVE, C.; KENNEDY, T.; MOOTS, R.; WILLIAMSON, P.; DICKSON, R. Rituximab for the treatment of rheumatoid arthritis. Health Technol. Assess., v.13, n.9, p.23-29, 2009.
2. BÉRTOLO, M.B.; BRENO, C.V.; SCHAINBERG, C.G.; NEUBARTH, F.; LIMA, F.A.C.D.; LAURINDO, I.M.; SILVEIRA, I.G.; PEREIRA, I.A.; LOURES, M.A.R.; AZEVEDO, M.N.D.; FREITAS, M.V.C.D.; NETO, M.D.S.P.; XAVIER, R.M.; GIORGI, R.D.N.; KOWALSKI, S.C.; ANTI, S.M.A. Atualização do consenso brasileiro no diagnóstico e tratamento da artrite reumatóide. Rev. Bras. Reumatol., v.47, n.3, p.151-159, 2007.
3. BRUCE, S.P. Recent Developments in the Treatment of Rheumatoid Arthritis. J. Pharm. Pract., v.22, n.1, p.65-74, 2009.
4. CORTEJOSO-FERNANDEZ, L.; ROMERO-JIMENEZ, M.R.; PERNIA-LOPEZ, M.S.; MONTORO-ALVAREZ, M.; SANJURJO-SAEZ, M. Effectiveness and safety of abatacept in moderate to severe rheumatoid arthritis. J. Pharm. Pharm. Sci., v.15, n.1, p.46-51, 2012.
5. CORTEJOSO-FERNÁNDEZ, L.; ROMERO-JIMÉNEZ, M.R.; MARÍA, S.P.-L.; MONTORO-ÁLVAREZ, M.; SANJURJO-SÁEZ, M. Effectiveness and Safety of Abatacept in Moderate to Severe Rheumatoid Arthritis. J. Pharm. Pharm. Sci., v.15, n.1, p.46-51, 2012.
6. FALGARONE, G.; SEMERANO, L.; RULLE, S.; BOISSIER, M.C. Targeting lymphocyte activation to treat rheumatoid arthritis. Joint Bone Spine, v.76, n.4, p.327-332, 2009.
7. GENANT, H.K.; PETERFY, C.G.; WESTHOVENS, R.; BECKER, J.C.; ARANDA, R.; VRATSANOS, G.; TENG, J.; KREMER, J.M. Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann. Rheum. Dis., v.67, n.8, p.1084-1089, 2008.
8. GENOVESE, M.C.; BECKER, J.C.; SCHIFF, M.; LUGGEN, M.; SHERRER, Y.; KREMER, J.; BIRBARA, C.; BOX, J.; NATARAJAN, K.; NUAMAH, I.; LI, T.; ARANDA, R.; HAGERTY, D.T.; DOUGADOS, M. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N. Engl. J. Med., v.353, n.11, p.1114-1123, 2005.
9. HAKKINEN, A.; KAUTIAINEN, H.; HANNONEN, P.; YLINEN, J.; MAKINEN, H.; SOKKA, T. Muscle strength, pain, and disease activity explain individual subdimensions of the Health Assessment Questionnaire disability index, especially in women with rheumatoid arthritis. Ann. Rheum. Dis., v.65, n.1, p.30-34, 2006.
10. HUEDO-MEDINA, T.B.; SANCHEZ-MECA, J.; MARIN-MARTINEZ, F.; BOTELLA, J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychology Methods, v.11, n.2, p.193-206, 2006.
11. JADAD, A.R.; MOORE, R.A.; CARROLL, D.; JENKINSON, C.; REYNOLDS, D.J.; GAVAGHAN, D.J.; MCQUAY, H.J. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control. Clin. Trials, v.17, n.1, p.1-12, 1996.
12. JONSSON, B.; KOBELT, G.; SMOLEN, J. The burden of rheumatoid arthritis and access to treatment: uptake of new therapies. Eur. J. Health Econ., v.8, suppl.2, p. S61-86, 2008.
13. KREMER, J.M.; DOUGADOS, M.; EMERY, P.; DUREZ, P.; SIBILIA, J.; SHERGY, W.; STEINFELD, S.; TINDALL, E.; BECKER, J.C.; LI, T.; NUAMAH, I.F.; ARANDA, R.; MORELAND, L.W. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum., v.52, n.8, p.2263-2271, 2005.
14. KREMER, J.M.; GENANT, H.K.; MORELAND, L.W.; RUSSELL, A.S.; EMERY, P.; ABUD-MENDOZA, C.; SZECHINSKI, J.; LI, T.; GE, Z.; BECKER, J.C.; WESTHOVENS, R. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann. Intern. Med., v.144, n.12, p.865-876, 2006.
15. MALAVIYA, A.P.; ÖSTÖR, A.J. Drug adherence to biologic DMARDS with a special emphasis on the benefits of subcutaneous abatacept. Patient Prefer. Adherence, v.6, p.589-596, 2012.
16. MOLA, E.M.; BALSA, A.; TABOADA, V.M.; SANMARTÍ, R.; MARENCO, J.L.; SARABIA, F.N.; GÓMEZ-REINO, J.; ÁLVARO-GRACIA, J.M.; IVORRA, J.A.R.; LOJO, L.; PLASENCIA, C.; CARMONA, L. El uso de abatacept en artritis reumatoide: revisión de la evidencia y recomendaciones. Reumatol. Clín., 2012. (in press). Available at: . Accessed on: 23 nov. 2012.
17. MORELAND, L.W.; ALTEN, R.; VAN DEN BOSCH, F.; APPELBOOM, T.; LEON, M.; EMERY, P.; COHEN, S.; LUGGEN, M.; SHERGY, W.; NUAMAH, I.; BECKER, J.C. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum., v.46, n.6, p.1470-1479, 2002.
18. RUBBERT-ROTH, A.; FINCKH, A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res. Ther., v.11 suppl 1, p. S1, 2009.
19. RUSSELL, A.; BERESNIAK, A.; BESSETTE, L.; HARAOUI, B.; RAHMAN, P.; THORNE, C.; MACLEAN, R.; DUPONT, D. Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis. Clinical Rheumatol., v.28, n.4, p.403-412, 2009.
20. RUSSELL, A.; BERESNIAK, A.; BESSETTE, L.; HARAOUI, B.; RAHMAN, P.; THORNE, C.; MACLEAN, R.; DUPONT, D. Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis. Clinical Rheumatol., v.28, n.4, p.403-412, 2009.
21. SALLIOT, C.; FINCKH, A.; KATCHAMART, W.; LU, Y.; SUN, Y.; BOMBARDIER, C.; KEYSTONE, E. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Ann. Rheum. Dis., v.70, n.2, p.266-271, 2011.
22. SCHIFF, M.; KEISERMAN, M.; CODDING, C.; SONGCHAROEN, S.; BERMAN, A.; NAYIAGER, S.; SALDATE, C.; LI, T.; ARANDA, R.; BECKER, J.C.; LIN, C.; CORNET, P.L.; DOUGADOS, M. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann. Rheum. Dis., v.67, n.8, p.1096-1103, 2008.
23. SINGH, J.A.; CHRISTENSEN, R.; WELLS, G.A.; SUAREZ-ALMAZOR, M.E.; BUCHBINDER, R.; LOPEZ-OLIVO, M.A.; GHOGOMU, E.T.; TUGWELL, P. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. Can. Med. Assoc. J., v.181, n.11, p.787-796, 2009.
24. SMOLEN, J.S.; ALETAHA, D.; KOELLER, M.; WEISMAN, M.H.; EMERY, P. New therapies for treatment of rheumatoid arthritis. Lancet, v.370, n.9602, p.1861-1874, 2007.
25. TANG, B.; RAHMAN, M.; WATERS, H.C.; CALLEGARI, P. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis. Clin. Ther., v. 30, n. 7, p. 1375-1384, 2008.
26. TOUSSIROT, E.; WENDLING, D. The use of TNF-alpha blocking agents in rheumatoid arthritis: an overview. Expert Opin. Pharmacother., v.5, n.3, p.581-594, 2004.
27. WEINBLATT, M.; COMBE, B.; COVUCCI, A.; ARANDA, R.; BECKER, J.C.; KEYSTONE, E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis Rheum., v.54, n.9, p.2807-2816, 2006.
28. WEINBLATT, M.; SCHIFF, M.; GOLDMAN, A.; KREMER, J.; LUGGEN, M.; LI, T.; CHEN, D.; BECKER, J.C. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann. Rheum. Dis., v.66, n.2, p.228-234, 2007.
29. WESTHOVENS, R.; ROBLES, M.; XIMENES, A.C.; NAYIAGER, S.; WOLLENHAUPT, J.; DUREZ, P.; GOMEZ-REINO, J.; GRASSI, W.; HARAOUI, B.; SHERGY, W.; PARK, S.H.; GENANT, H.; PETERFY, C.; BECKER, J.C.; COVUCCI, A.; HELFRICK, R.; BATHON, J. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann. Rheum. Dis., v.68, n.12, p.1870-1877, 2009a.
30. WESTHOVENS, R.; KREMER, J.M.; MORELAND, L.W.; EMERY, P.; RUSSELL, A.S.; LI, T.; ARANDA, R.; BECKER, J.C.; QI, K.; DOUGADOS, M. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. J. Rheumatol., v.36, n.4, p.736-742, 2009b.
31. ZHANG, J.; YU, K.F. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. Jama, v.280, n.19, p.1690-1691, 1998.